COD test data

The Wellesley, Mass., company announced results of retrospective trials of its COD test for detecting the human carcinoma antigen in blood serum in 273 samples.

The test recognized progression or recurrence of breast cancer one to eight months in advance of detection by physicians in a study of 131 retrospective samples, with sensitivity of 62.5 percent. In a study of 142 samples, the test had better sensitivity and specificity than the CEA and CA 15.3 assays. ...